AbCellera is breaking the barriers of conventional antibody drug development to bring better medicines to patients, sooner.
AbCellera’s engine integrates expert teams, technology, and facilities with the data science and automation needed to propel antibody-based medicines from target to clinic in nearly every therapeutic area with precision and speed. AbCellera has developed specific antibody discovery and development technologies to unlock high-value drug classes and targets, including T-cell engagers for cancer and transmembrane proteins for indications including metabolic and endocrine conditions, pain, autoimmunity and more.
Notable Press Mentions
AbCellera to make C$701 million co-investment in Canada
How AbCellera helps partners propel their antibody therapies to the clinic
AbCellera Continues Partnership Frenzy with AbbVie Antibody Discovery Pact
Regeneron advances first program from AbCellera collaboration into further preclinical development
A year after embarking on a new HQ and manufacturing site, AbCellera starts second phase of its buildout
Versant biotechs hand AbCellera antibody discovery wish list as part of multiyear deal with the VC shop